Why is Trulieve Cannabis stock sliding today?

Trulieve Cannabis' shares dipped 6.5% in pre-market trading following the company's announcement of a licensing deal with Connected Cannabis on Monday. The agreement grants Trulieve exclusive rights to the Alien Labs and Connected brands in Florida and Texas, allowing the company to expand its product offerings. However, investors reacted negatively to the news, likely due to concerns over the deal's potential financial impact and execution risks.

Trulieve's CEO, Kim Rivers, announced earlier this year a plan to sell around 2.5 million shares through a Rule 10b5-1 plan, with additional sales becoming eligible after September 15, 2026. This insider selling pressure has been ongoing and may be exacerbated by institutional holders rebalancing their portfolios following Trulieve's inclusion in major market indices on September 22.

With the S&P 500 essentially unchanged today and the Nasdaq marginally down, there is no sector-wide support for cannabis stocks. Trulieve's recent financial performance was mixed, with revenue down 10% year-over-year in Q2 FY2026 and a significant net loss. These factors, combined with market skepticism regarding the short-term effects of the licensing deal, have contributed to the stock's decline, while the company's long-term prospects, such as its NYSE listing and DEA registration milestones, remain unaffected.